Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers

Autor: Eden Schwartz, Nicolas Boissel, Anne Brignier, Isabelle Madelaine, Nathalie Parquet, André Desproges, Sarah Mukenyi, Lorène Magdelonnette, Chloé Talarmin, Emmanuelle Lesprit, André Baruchel, Catherine Thieblemont, Steven Kerob, Jérôme Larghero, Miryam Mebarki, François Cartier

Publikováno v: Cytotherapy
Cytotherapy, Elsevier, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩
Cytotherapy, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩

International audience; Background aims: According to European Directive 2001/83/EC, chimeric antigen receptor T (CAR T) cells belong to a new class of medicines referred to as advanced therapy medicinal products (ATMPs). The specific features and co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2314eace724f4eff1791a6601f770943
https://pubmed.ncbi.nlm.nih.gov/32732084